Red Light For Seres Therapeutics, But Not A Stop Light For Me
Summary
- Seeking Alpha’s metrics give Seres Therapeutics a “Very Bearish” quant rating.
- I agree with Seeking Alpha’s assessment based on its performance, but there are reasons why this might change.
- Nestle is a strong supporter of Seres and recently injected $175 million to acquire further rights to its SER-109 C.difficile product and rights to market other products in North America.
- Seres announced a manufacturing partnership for SER-109 with Swiss contract development and manufacturing company Bacthera.
- The likelihood that SER-109 gets FDA designation as the first microbiomics product seems high and relatively near term.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of MCRB, PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.